Development of the treatment for fulminant type1 diabetes using the model mouse
| Project/Area Number |
21591149
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Metabolomics
|
|---|
| Research Institution | Osaka Medical College |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SANO Hiroyuki 大阪医科大学, 医学部, 助教 (20556435)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 劇症1型糖尿病 / encephalomyocarditis virus / GLP-1 / マクロファージ / 膵島移植 / 膵β細胞再生 / 脂肪組織由来幹細胞 / exendin-4 / マイクロアレイ / 免疫染色 / ウイルス |
|---|
| Research Abstract |
This study has shown that exendin-4 suppresses the onset of encephalomyocarditis virus(EMCV) induced diabetes, which is a model of fulminant type 1 diabetes. Exendin-4 markedly reducedβ cell destruction by inhibiting the infiltration of macrophages into the islets and the expression of EMCV infected macrophage derived chemical mediators, TNF-α, IL-1β and iNOS. Our study clarified that it could be an important strategy to suppress macrophage activation in the treatment of fulminant type1 diabetes.
|
Report
(4 results)
Research Products
(19 results)
